An Alzheimer Vaccine by a Spanish biopharma company?

The vaccine targets the Aβ40 peptide, known to be involved in Alzheimer's disease.

Araclon Biotech's Alzheimer's vaccine, ABvac40, showed a clean safety profile in a Phase II analysis.

The vaccine targets the Aβ40 peptide, known to be involved in Alzheimer's disease.

While the trial wasn't designed to test efficacy, the treated group showed a 38% reduction in disease progression.

ABvac40 may address cognitive decline in Alzheimer's, but global functional scales didn't show a significant difference.

The vaccine's design prevents a previous side effect, meningoencephalitis.

Vaxxinity is currently the company who has the most advanced Alzheimer's vaccine, with Phase IIa data suggesting potential advantages, but it's seeking a pharma partner for Phase III.

---

→ More key information about Araclon Biotech:

Araclon Biotech, established in 2004 as a University of Zaragoza spin-off, has evolved into a pioneering company in Alzheimer's disease research since Grifols became a shareholder in 2012.

They've developed tests to analyze β-amyloid peptides in human plasma, aiding in the early detection of AD-related changes in cognitively normal individuals.

Their central laboratories in Zaragoza, Spain, serve as the headquarters, offering the ABtest Service for peptide determination in human plasma.

Araclon Biotech holds multiple patent families safeguarding their diagnostic assays (IP ABtest42/40, IP ABtestMS) and active immunotherapies (IP ABvac40, IP ABvac42).